Incyte has announced it has entered into an asset purchase agreement with MorphoSys, giving Incyte exclusive global development and commercialisation rights to tafasitamab, to be marketed in the US as Monjuvi® and outside the US as Minjuvi®.
In a previous agreement, MorphoSys and Incyte signed a global collaboration and license agreement for tafasitamab. In the US, MorphoSys and Incyte will co-commercialise tafasitamab, with MorphoSys leading the commercialisation strategy. Outside the US, Incyte will have exclusive commercialisation rights, and will lead the commercialisation strategy.